ASKA Pharmaceutical Holdings Co (TSE:4886) Capex-to-Revenue : 0.00 (As of Dec. 2023)

ASKA Pharmaceutical Holdings Co Capex-to-Revenue Chart

ASKA Pharmaceutical Holdings Co Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Capex-to-Revenue	Get a 7-Day Free Trial							-	-	-	-	-

Competitive Comparison of ASKA Pharmaceutical Holdings Co's Capex-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, ASKA Pharmaceutical Holdings Co's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ASKA Pharmaceutical Holdings Co's Capex-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, ASKA Pharmaceutical Holdings Co's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where ASKA Pharmaceutical Holdings Co's Capex-to-Revenue falls into.

ASKA Pharmaceutical Holdings Co Capex-to-Revenue Calculation

ASKA Pharmaceutical Holdings Co's Capex-to-Revenue for the fiscal year that ended in Mar. 2024 is calculated as

ASKA Pharmaceutical Holdings Co's Capex-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ASKA Pharmaceutical Holdings Co  (TSE:4886) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.

ASKA Pharmaceutical Holdings Co Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of ASKA Pharmaceutical Holdings Co's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

ASKA Pharmaceutical Holdings Co (TSE:4886) Business Description